Showing 5441-5450 of 6964 results for "".
- Label Update: Simponi Aria Improves Fatigue in PsA, RAhttps://practicaldermatology.com/news/label-update-simponi-aria-improves-fatigue-in-psa-ra/2460699/Simponi Aria (golimumab) from Janssen Pharmaceutical Company of Johnson & Johnson is the first and only fully human anti-tumor necrosis factor (TNF) biologic approved by the FDA to include language in its product label stating that the treatment results in improvement in fatigue for adul
- AbbVie, Evolus Agree to Settlementhttps://practicaldermatology.com/news/abbvie-evolus-agree-to-settlement/2460697/AbbVie, Evolus, and Medytox have agreed to a new settlement to fully resolve all outstanding litigation, including the US International Trade Commission (ITC) case regarding the sale of Jeuveau®, between the companies. A California court case filed by Medytox against Evolus will be
- Researchers Identify Mechanisms That Are Essential for Proper Skin Developmenthttps://practicaldermatology.com/news/researchers-identify-mechanisms-that-are-essential-for-proper-skin-development/2460696/Mount Sinai researchers have discovered that Polycomb complexes, groups of proteins that maintain gene expression patterns, are essential for proper skin development, according to a paper published in Genes & Development. This discovery could improve develop
- Industry Responds to COVID-19: NoSweathttps://practicaldermatology.com/news/industry-responds-to-covid-19-nosweat/2460695/Recognizing that any physical activity coupled with wearing a face shield can produce sweat that can get in the eyes and fog-up shields, NoSweat has created the first disposable performance liners specifically for face shields that absorb sweat while preventing fogging, odors, stains, and even ac
- Industry Responds to COVID-19: Janssen Pharmaceutical Companieshttps://practicaldermatology.com/news/industry-responds-to-covid-19-nosweat-janssen-pharmaceutical-companies/2460694/In response to the COVID-19 pandemic, Janssen Pharmaceutical Companies of Johnson & Johnson, “has been collaborating with regulators, healthcare organizations, institutions and communities worldwide to help ensure our research platforms, existi
- COVID-19, the Stock Market, and Dermatologyhttps://practicaldermatology.com/news/covid-19-the-stock-market-and-dermatology/2460688/By Amylee Martin, BS, Akshitha Thatiparthi, BS, Jeffrey Liu, BS, Jashin J. Wu, MD Novel coronavirus, COVID-19, is not only a major public health threat but has also impacted the economy. Due to the pandemic, experts predict a 0.5% decrease in t
- Almirall’s Klisyri Performs Well in Phase III AK Trialshttps://practicaldermatology.com/news/almiralls-klisyri-performs-well-in-phase-iii-ak-trials/2460687/Almirall’s Klisyri (tirbanibulin) ointment demonstrated complete clearance of actinic keratosis (AK) lesions at day 57 in treated face or scalp areas in a significantly higher number of patients than vehicle, according to Phase III trials. What’s more, Klisyri is safe with n
- DermTech Adds to Scientific Advisory Boardhttps://practicaldermatology.com/news/dermtech-adds-to-scientific-advisory-board/2460686/Drs. Lisa Beck and George Han are the newest members of DermTech’s Scientific Advisory Board, Lisa Beck, MD, is the co-director of the University of Rochester Medical Center for Allergic Disease Research a
- New ASDS Guideline Addresses Prevention and Treatment of Filler Complicationshttps://practicaldermatology.com/news/new-asds-guideline-on-preventing-and-treating-filler-complications/2460685/The American Society for Dermatologic Surgery (ASDS) Multispecialty Soft-tissue Fillers Guideline Task Force has
- FDA Clears CellFX from Pulse Bioscienceshttps://practicaldermatology.com/news/fda-clears-cellfx-from-pulse-biosciences/2460682/The FDA has cleared the CellFX® System from Pulse Biosciences, Inc. for dermatologic procedures requiring ablation and resurfacing of the skin, and a controlled commercial launch will soon begin in the US with a select group of leaders in aesthetic dermatology. The